Article
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Science translational medicine - 8 Feb 2012
Katayama Ryohei, Shaw Alice T, Khan Tahsin M, Mino-Kenudson Mari, Solomon Benjamin J, Halmos Balazs, Jessop Nicholas A, Wain John C, Yeo Alan Tien, Benes Cyril, Drew Lisa, Saeh Jamal Carlos, Crosby Katherine, Sequist Lecia V, Iafrate A John, Engelman Jeffrey A
Abstract excerpt
Most anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancers (NSCLCs) are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However, patients with these cancers invariably relapse, typically within 1 year, because of the development of drug resistance. Herein, we report findings from a series of lung cancer patients (n = 18) with acquired resistance to the ALK TKI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.